Clinical trials: Prevalent OPG and RANKL Excession in Patients With CAD
Prevalent OPG and RANKL Excession in Patients With CAD
Graz Osteoprotegerin as a Risk Factor (GORF) Study
Osteoprotegerin (OPG) is membrane bound in the immune system but can also be produced and secreted almost everywhere in the organism, so that it is mainly available in soluble form.
- Trial name
- NCT01574963
- Where
- Austria
- Volunteers
- 150 people
- Sponsor
- Medical University of Graz